中华微生物学和免疫学杂志
中華微生物學和免疫學雜誌
중화미생물학화면역학잡지
CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY
2013年
6期
423-428
,共6页
殷丽丽%韩晓旭%赵彬%张旻%安明晖%吉阳涛%欧阳金鸣%尚红
慇麗麗%韓曉旭%趙彬%張旻%安明暉%吉暘濤%歐暘金鳴%尚紅
은려려%한효욱%조빈%장민%안명휘%길양도%구양금명%상홍
HIV-1%Y181C%H221Y%复制能力
HIV-1%Y181C%H221Y%複製能力
HIV-1%Y181C%H221Y%복제능력
HIV-1%Y181C%H221Y%Replication capacity
目的 明确中国经抗病毒治疗HIV-1感染者中Y181C突变与H221Y突变发生情况及H221Y突变对Y181C突变株复制能力的影响.方法 选取河南省经高效抗逆转录病毒治疗出现Y181C和H221Y双突变的B'亚型HIV-1感染者3例.回顾性检测其2004-2006年间抗病毒治疗后每6个月一次的随访血样,从血浆中扩增病毒pol区基因,克隆入T载体并测序,分析克隆中Y181C及H221Y突变的存在情况.构建Y181C单突变质粒及Y181C和H221Y双突变质粒,分别与包膜蛋白质粒pVSV-G共转染HEK 293T细胞,包装两种突变型假病毒.分别单轮感染TZM-bl细胞,分析两种突变型假病毒单轮复制能力差异.结果 共获得3例患者来自6个随访点的57条TA克隆序列,其中Y181C单突变克隆46个,Y181C和H221Y双突变克隆35个,H221Y突变均出现于已经存在Y181C突变的克隆中.在2例患者的两组假病毒中,携带Y181C和H221Y双突变假病毒的复制能力分别是Y181C单突变假病毒的1.42倍和1.62倍.结论 在经抗病毒治疗的B'亚型HIV-1感染者中,H221Y突变很可能为Y181C突变的补偿突变,提高Y181C突变株复制能力.这一发现对中国B'亚型HIV-1感染者耐药基因型检测结果的解读及指导临床进行抗病毒治疗具有重要意义.
目的 明確中國經抗病毒治療HIV-1感染者中Y181C突變與H221Y突變髮生情況及H221Y突變對Y181C突變株複製能力的影響.方法 選取河南省經高效抗逆轉錄病毒治療齣現Y181C和H221Y雙突變的B'亞型HIV-1感染者3例.迴顧性檢測其2004-2006年間抗病毒治療後每6箇月一次的隨訪血樣,從血漿中擴增病毒pol區基因,剋隆入T載體併測序,分析剋隆中Y181C及H221Y突變的存在情況.構建Y181C單突變質粒及Y181C和H221Y雙突變質粒,分彆與包膜蛋白質粒pVSV-G共轉染HEK 293T細胞,包裝兩種突變型假病毒.分彆單輪感染TZM-bl細胞,分析兩種突變型假病毒單輪複製能力差異.結果 共穫得3例患者來自6箇隨訪點的57條TA剋隆序列,其中Y181C單突變剋隆46箇,Y181C和H221Y雙突變剋隆35箇,H221Y突變均齣現于已經存在Y181C突變的剋隆中.在2例患者的兩組假病毒中,攜帶Y181C和H221Y雙突變假病毒的複製能力分彆是Y181C單突變假病毒的1.42倍和1.62倍.結論 在經抗病毒治療的B'亞型HIV-1感染者中,H221Y突變很可能為Y181C突變的補償突變,提高Y181C突變株複製能力.這一髮現對中國B'亞型HIV-1感染者耐藥基因型檢測結果的解讀及指導臨床進行抗病毒治療具有重要意義.
목적 명학중국경항병독치료HIV-1감염자중Y181C돌변여H221Y돌변발생정황급H221Y돌변대Y181C돌변주복제능력적영향.방법 선취하남성경고효항역전록병독치료출현Y181C화H221Y쌍돌변적B'아형HIV-1감염자3례.회고성검측기2004-2006년간항병독치료후매6개월일차적수방혈양,종혈장중확증병독pol구기인,극륭입T재체병측서,분석극륭중Y181C급H221Y돌변적존재정황.구건Y181C단돌변질립급Y181C화H221Y쌍돌변질립,분별여포막단백질립pVSV-G공전염HEK 293T세포,포장량충돌변형가병독.분별단륜감염TZM-bl세포,분석량충돌변형가병독단륜복제능력차이.결과 공획득3례환자래자6개수방점적57조TA극륭서렬,기중Y181C단돌변극륭46개,Y181C화H221Y쌍돌변극륭35개,H221Y돌변균출현우이경존재Y181C돌변적극륭중.재2례환자적량조가병독중,휴대Y181C화H221Y쌍돌변가병독적복제능력분별시Y181C단돌변가병독적1.42배화1.62배.결론 재경항병독치료적B'아형HIV-1감염자중,H221Y돌변흔가능위Y181C돌변적보상돌변,제고Y181C돌변주복제능력.저일발현대중국B'아형HIV-1감염자내약기인형검측결과적해독급지도림상진행항병독치료구유중요의의.
Objective To explore the development of Y181C and H221Y mutations among HIV-1 infected patients upon antiretroviral therapy in China and to investigate the impact of H221Y mutation on replication capacity of Y181C mutant.Methods Three HIV-1 subtype B' infected patients with Y181C and H221Y mutations upon highly active antiretroviral therapy from Henan province were enrolled in this study.Follow-up blood samples collected every six months from the patients after therapy between 2004 to 2006 were detected for viral load evaluation.Fragments of pol gene were amplified by nested PCR.The purified PCR products were ligated into pMD18-T vector to construct recombinant plasmids,which were further sequenced and compared with the HIV reference strain from Stanford HIVDB for analyzing the development of Y181C and H221Y mutations.Plasmids containing Y181C mutation alone and plasmids containing Y181C and H221Y double mutations were constructed and cotransfected respectively with envelope-expression plasmid pVSV-G into HEK 293T cells to obtain HIV-1 pseudotyped viruses.Replication capacity of each pseudotyped virus was analyzed after a single-cycle infection in TZM-bl cells.Results A total of 57 TA cloned sequences from six follow-up blood samples of three patients were obtained.Y181C mutation alone was found in 46 clones and Y181C and H221Y mutations were found in 35 clones.Moreover,H221Y mutation was only found in clones in which Y181C mutation had already developed.Between two pairs of pseudotyped virus from two patients,replication capacity of those viruses containing Y181C and H221Y mutations were 1.42 and 1.62 fold higher than the viruses containing Y181C mutation alone,respectively.Conclusion H221Y mutation might be a compensatory mutation of Y181C mutation occurred to improve the replication capacity of viral strains with Y181C mutant in HIV-1 subtype B' infected patients upon antiretroviral therapy.The finding suggests that it's significantly important to further perform the genotypic test for HIV-1 subtype B' drug resistance in order to guide antiretroviral treatment in clinical in China.